These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9664010)

  • 1. Incidence of hypercalcaemia in haemodialysis patients.
    Pascual N; Andrea C; Zaleski M; Hernandez J; Goicoechea M
    EDTNA ERCA J; 1997; 23(3):48-50. PubMed ID: 9664010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 5. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis.
    Pflanz S; Henderson IS; McElduff N; Jones MC
    Nephrol Dial Transplant; 1994; 9(8):1121-4. PubMed ID: 7800211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can hypercalcaemia be avoided during oral calcitriol pulse therapy of secondary hyperparathyroidism in haemodialysis patients?
    Szotkiewicz M; Zdrojewski Z; Swima-Gillow A; Rutkowski B
    Nephrol Dial Transplant; 1995; 10(9):1781-2. PubMed ID: 8559511
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and efficacy of calcium carbonate in children with chronic renal failure.
    Clark AG; Oner A; Ward G; Turner C; Rigden SP; Haycock GB; Chantler C
    Nephrol Dial Transplant; 1989; 4(6):539-44. PubMed ID: 2507975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The control of hyperphosphataemia in haemodialysis patients.
    Papayianni L; Katopodis K; Kosmanou J; Banioti A; Katsaraki A; Palatzidou M; Prokopiou F; Betsiou V; Siamopoulos KC
    EDTNA ERCA J; 1997; 23(4):25-7. PubMed ID: 9664020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis.
    Okada K; Takahashi S; Nagura Y; Hatano M
    Nihon Jinzo Gakkai Shi; 1989 Oct; 31(10):1085-9. PubMed ID: 2615019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance haemodialysis.
    Saif I; Halim A; Altaf A; Saif M; Khalid M; Ahmad D; Imran H
    J Ayub Med Coll Abbottabad; 2007; 19(4):26-8. PubMed ID: 18693591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium carbonate as an alternative to aluminium hydroxide in maintenance haemodialysis for chronic renal failure.
    O'Brien A; McParland C; Keogh B
    Ir Med J; 1987 Feb; 80(2):68-70. PubMed ID: 3557928
    [No Abstract]   [Full Text] [Related]  

  • 13. Six cases of successful cinacalcet cessation in haemodialysis patients treated for secondary hyperparathyroidism.
    Jean G; Chazot C; Charra B
    Nephrol Dial Transplant; 2007 Jul; 22(7):2102-3. PubMed ID: 17395648
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hyperparathyroidism and parathyroidectomy in dialyzed patients].
    Sotorník I; Slavíková M; Kocandrle V; Lukác M; Petrásek R; Dutka J; Zichová M
    Vnitr Lek; 1993 May; 39(5):470-5. PubMed ID: 8351879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [2 dialysis cases which came to our clinic for the symptoms caused by hypercalcemia].
    Shin J; Nishioka M; Shinko S; Yamamoto T; Shibuya K; Kasumoto H; Bito Y; Fujita Y; Komaba K
    Clin Calcium; 2005 Sep; 15 Suppl 1():87-91; discussion 91. PubMed ID: 16272638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
    J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypercalcaemia is associated with poor mental health in haemodialysis patients: results from Japan DOPPS.
    Tanaka M; Yamazaki S; Hayashino Y; Fukuhara S; Akiba T; Saito A; Asano Y; Port FK; Kurokawa K; Akizawa T
    Nephrol Dial Transplant; 2007 Jun; 22(6):1658-64. PubMed ID: 17298993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lanthanum: new drug. Hyperphosphataemia in dialysis patients: more potential problems than benefits.
    Prescrire Int; 2007 Apr; 16(88):47-50. PubMed ID: 17458039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cinacalcet: new drug. Secondary hyperparathyroidism: where are the clinical data?
    Prescrire Int; 2006 Jun; 15(83):90-3. PubMed ID: 16764095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.